[Form 4] Beta Bionics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Beta Bionics, Inc. director Adam Lezack reported an equity award of 3,997 shares of common stock. The Form 4 shows that on January 13, 2026, he acquired 3,997 shares at a price of $0 per share, reflecting a grant rather than an open-market purchase. A footnote explains that this represents a restricted stock unit award granted under the company’s 2025 Equity Incentive Plan. Following this grant, Lezack beneficially owns 12,432 shares of Beta Bionics common stock, held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lezack Adam

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,997	$0.00	--

Holdings After Transaction: Common Stock — 12,432 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lezack Adam

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/13/2026		A		3,997(1)	A	$0	12,432	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

	/s/ Stephen Feider, Attorney-in-Fact	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Adam Lezack report for Beta Bionics (BBNX)?

Adam Lezack reported the acquisition of 3,997 shares of Beta Bionics, Inc. common stock on January 13, 2026, as disclosed on a Form 4 filing.

Was the Beta Bionics (BBNX) Form 4 transaction a stock grant or a market purchase?

The transaction was a restricted stock unit award, not a market purchase. The 3,997 shares were granted at a price of $0 per share under the 2025 Equity Incentive Plan.

How many Beta Bionics (BBNX) shares does Adam Lezack own after this Form 4 transaction?

After the reported transaction, Adam Lezack beneficially owns 12,432 shares of Beta Bionics, Inc. common stock, held directly.

What role does Adam Lezack have at Beta Bionics (BBNX)?

Adam Lezack is reported as a director of Beta Bionics, Inc. on the Form 4, with no officer or 10% owner status indicated.

Under which plan were the 3,997 Beta Bionics (BBNX) shares granted to Adam Lezack?

The 3,997-share award was granted under Beta Bionics, Inc.’s 2025 Equity Incentive Plan as a restricted stock unit grant.

Was Adam Lezack’s Beta Bionics (BBNX) Form 4 transaction reported as direct or indirect ownership?

The shares reported on the Form 4 are shown as direct (D) ownership, with no indirect beneficial ownership described.